Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6619026 | 1.00 | SIGMAR1 (0.49) | SIGMAR1OPRK1RAB9AUTS2RALDH1A1 | |
| SCHEMBL8187086 | 0.84 | MAPT (0.42) | RAB9AUTS2RALDH1A1LMNAKMT2A | |
| SCHEMBL6480095 | 0.83 | UTS2R (0.48) | OPRK1UTS2R | |
| Hydrochloric Acid SCHEMBL8668980 | 0.82 | RAB9A (0.47) | SIGMAR1OPRK1RAB9AALDH1A1ACHE | |
| Hydrochloric Acid SCHEMBL5629607 | 0.82 | OPRK1 (0.48) | SIGMAR1OPRK1RAB9AUTS2RALDH1A1 | |
| Hydrochloric Acid SCHEMBL6358404 | 0.82 | OPRK1 (0.48) | SIGMAR1OPRK1RAB9AUTS2RALDH1A1 | |
| Hydrochloric Acid SCHEMBL5629634 | 0.79 | OPRK1 (0.52) | SIGMAR1OPRK1RAB9AALDH1A1KMT2A | |
| Hydrochloric Acid SCHEMBL5629641 | 0.79 | OPRK1 (0.52) | SIGMAR1OPRK1RAB9AALDH1A1KMT2A | |
| Hydrochloric Acid SCHEMBL8096349 | 0.77 | UTS2R (0.54) | SIGMAR1RAB9AUTS2RALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL5631322 | 0.75 | OPRK1 (0.49) | SIGMAR1OPRK1RAB9AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050020576-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | ADOLOR CORPORATION | 2005-01-27 | — | — | US | disclosed |
| US-6750216-B2 | HETEROCYCLIC AMINES SUCH AS 2-(2-(N-METHYLSULFAMOYL)-4-METHOXY -PHENYL)-N-METHYL-N-((1S)-1-PHENYL-2-((1-PYRROLIDINYL)ETHYL)) ACETAMIDE, ADMINISTERED AS ANALGESICS | ADOLOR CORPORATION | 2004-06-15 | — | — | US | disclosed |
| US-20030144272-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | ADOLOR CORPORATION | 2003-07-31 | — | — | US | disclosed |
| US-6486165-B2 | TREATING WITH AGONISTS AT KAPPA OPIOID RECEPTORS SUCH AS METHYL-4-(2-GLYCYL-4-(TRIFLUOROMETHYLPHENYL)ACETYL)-3-(R,S)-((1 -PYRROLIDINYL)-METHYL)-1-PIPERAZINECARBOXYLATE | ADOLOR CORPORATION | 2002-11-26 | — | — | US | disclosed |
| US-6476063-B2 | DEVOID OF CENTRAL NERVOUS SYSTEM EFFECTS; TOPICAL AND SYSTEMIC ADMINISTRATION; ANTIPRURITIC AGEENTS; ANALGESICS 1-ARYLMETHYLCARBONYL-2-PYRROLIDIN-1-YL-PIPERAZINES | ADOLOR CORPORATION | 2002-11-05 | — | — | US | disclosed |
| US-20020103164-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | ADOLOR CORPORATION | 2002-08-01 | — | — | US | disclosed |
| US-6391910-B1 | OPIOID ANTAGONIST; ANALGESIC | ADOLOR CORPORATION | 2002-05-21 | — | — | US | disclosed |
| US-6239154-B1 | ARYLACETAMIDES, AGONISTS AT KAPPA OPIOID RECEPTORS. | ADOLOR CORPORATION | 2001-05-29 | — | — | US | disclosed |
| US-6054445-A | KAPPA OPIOID AGONIST ACTIVITY; ANALGESICS AND ANTI-PRURITIC AGENTS | ADOLOR CORPORATION (US) | 2000-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103164-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | OPRK1, OPRD1, HRH4 | SIGMAR1 19/4885OPRK1 1/4885RAB9A 1572/4885 |
| US-20030144272-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | OPRK1, OPRD1, OPRM1 | SIGMAR1 5/4885OPRK1 1/4885RAB9A 1518/4885 |
| US-20050020576-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | OPRK1, OPRD1, OPRM1 | SIGMAR1 5/4885OPRK1 1/4885RAB9A 1595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.